TI
SUPN icon

Trexquant Investment’s Supernus Pharmaceuticals SUPN Stock Holding History

Trexquant Investment’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Buy
+7,554
New +$363K ﹤0.01% 1711
2025
Q3 		– Sell
-31,233
Closed -$984K – 1902
2025
Q2 		$984K Sell
31,233
-113,261
-78% -$3.63M 0.01% 1109
2025
Q1 		$4.73M Buy
144,494
+70,219
+95% +$2.49M 0.06% 529
2024
Q4 		$2.69M Sell
74,275
-20,677
-22% -$728K 0.03% 757
2024
Q3 		$2.96M Buy
+94,952
New +$2.96M 0.04% 665
2024
Q1 		– Sell
-18,122
Closed -$524K – 1774
2023
Q4 		$524K Sell
18,122
-11,887
-40% -$315K 0.01% 1068
2023
Q3 		$827K Buy
30,009
+17,390
+138% +$529K 0.02% 827
2023
Q2 		$379K Sell
12,619
-33,896
-73% -$1.19M 0.01% 1108
2023
Q1 		$1.69M Buy
46,515
+22,855
+97% +$879K 0.05% 518
2022
Q4 		$844K Buy
+23,660
New +$822K 0.02% 708
2021
Q3 		– Sell
-12,054
Closed -$371K – 1473
2021
Q2 		$371K Buy
+12,054
New +$370K 0.03% 618
2021
Q1 		– Sell
-10,650
Closed -$268K – 1450
2020
Q4 		$268K Buy
+10,650
New +$229K 0.03% 758
2020
Q1 		– Sell
-10,832
Closed -$257K – 1405
2019
Q4 		$257K Buy
+10,832
New +$263K 0.02% 813
2019
Q2 		– Sell
-82,901
Closed -$2.9M – 1105
2019
Q1 		$2.9M Buy
82,901
+21,524
+35% +$801K 0.21% 137
2018
Q4 		$2.04M Buy
+61,377
New +$2.64M 0.13% 235
2018
Q1 		– Sell
-14,392
Closed -$574K – 1363
2017
Q4 		$574K Buy
+14,392
New +$569K 0.06% 466
2017
Q1 		– Sell
-22,000
Closed -$556K – 1324
2016
Q4 		$556K Buy
+22,000
New +$492K 0.09% 390
2016
Q2 		– Sell
-67,382
Closed -$1.03M – 1089
2016
Q1 		$1.03M Buy
67,382
+12,567
+23% +$164K 0.12% 288
2015
Q4 		$737K Buy
+54,815
New +$848K 0.06% 521
2015
Q2 		– Sell
-59,000
Closed -$713K – 1228
2015
Q1 		$713K Buy
+59,000
New +$557K 0.07% 530

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Trexquant Investment's SUPN Position: Q2 2026 in Review

Trexquant Investment opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 7,554 shares worth $351K. The stake represents ﹤0.01% of the portfolio and ranks #1711 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in SUPN as recently as Q2 2025.

Trexquant Investment first reported a position in SUPN in Q1 2015 and has held it in 20 quarters since. The position peaked at $4.73M in Q1 2025. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Trexquant Investment held 7,554 shares of Supernus Pharmaceuticals worth $351K as of Q2 2026.
  • Supernus Pharmaceuticals was a new Trexquant Investment position in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Trexquant Investment's portfolio in Q2 2026, its #1711 holding.
  • Trexquant Investment first reported a position in Supernus Pharmaceuticals in Q1 2015 and has held it in 20 quarters since.
  • Trexquant Investment's Supernus Pharmaceuticals position peaked at $4.73M in Q1 2025.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.